EPS HEALTH TECH (03860) issues profit warning, expects interim after-tax loss to increase by approximately HK$8 million to approximately HK$12 million
EPS HEALTH TECH (03860) announces that the Group is expected to record an increase in after-tax loss of approximately HK$8 million to approximately HK$12 million for the six months ended 30 September 2026 compared with the corresponding period in 2025. The expected increase in loss for the current period compared with the corresponding period in 2025 is primarily attributable to the decline in revenue from the IRO and CRO services business due to highly intense market competition, as well as the decrease in gross profit of the healthcare products and pharmaceutical business affected by rising procurement costs and clearance of low-priced inventory. During the current period, in view of the challenging market environment, the Group also expects the garment business to record a segment loss of approximately HK$2 million, which is comparable to the corresponding period in 2025.
EPS HEALTH TECH (03860) has issued an announcement that the Group expects to record an increase in after-tax loss of approximately HK$8 million to approximately HK$12 million for the six months ended 30 September 2026 compared with the corresponding period in 2025. The expected increase in loss for the current period compared with the corresponding period in 2025 was primarily due to a decline in revenue from the IRO and CRO services business as a result of very intense market competition, as well as a decrease in gross profit from the healthcare products and pharmaceutical business affected by rising procurement costs and clearance of low-priced inventory. During the current period, given the challenging market environment, the Group also expects the apparel business to record a segment loss of approximately HK$2 million, which is comparable to the corresponding period in 2025.
Related Articles
Optimistic about continued growth in AI inference demand, Freedom upgrades Cerebras (CBRS.US) rating to "Buy," wafer-scale chip advantages draw attention.
US Stock Market Move | Planning to Raise $60 Billion to Pave the Way for Computing Power for AI Companies Broadcom Inc.(AVGO.US) Rose About 2.9%
Muse user growth momentum is strong, but long-term monetization prospects remain uncertain; BNP Paribas maintains an "Outperform" rating on Meta (META.US).
Optimistic about continued growth in AI inference demand, Freedom upgrades Cerebras (CBRS.US) rating to "Buy," wafer-scale chip advantages draw attention.
US Stock Market Move | Planning to Raise $60 Billion to Pave the Way for Computing Power for AI Companies Broadcom Inc.(AVGO.US) Rose About 2.9%
Muse user growth momentum is strong, but long-term monetization prospects remain uncertain; BNP Paribas maintains an "Outperform" rating on Meta (META.US).
